Drug Repositioning Meets Precision in Glioblastoma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29133572.
- Also identified by DOI 10.1158/1078-0432.CCR-17-2989.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glioblastoma has a gigantic unmet medical need. Molecular knowledge has evolved substantially, including data on clonal selection with progression. Past trials for all-comers may have produced false negative results. Molecular precision at progression needs workup of new tissue, and revisiting drugs with a focus on brain tumor penetration may yield surprises. <i>Clin Cancer Res; 24(2); 256-8. ©2017 AACR</i><i>See related article by Byron et al., p. 295</i>.
Medical subject headings
- Brain Neoplasms
- Glioblastoma